This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Feng, X.
Right arrow Articles by Jiang, X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Feng, X.
Right arrow Articles by Jiang, X.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2007, p. 324-331, Vol. 51, No. 1
0066-4804/07/$08.00+0     doi:10.1128/AAC.00627-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Library Screen for Inhibitors Targeting Norovirus Binding to Histo-Blood Group Antigen Receptors{triangledown}

Xizhi Feng and Xi Jiang*

Division of Infectious Diseases, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio

Received 22 May 2006/ Returned for modification 20 July 2006/ Accepted 16 October 2006

Human noroviruses (NVs) are a common cause of nonbacterial gastroenteritis. The disease is difficult to control due to its widespread nature and the lack of antivirals or vaccines against NVs. The recent identification of human histo-blood group antigens (HBGAs) as NV receptors opens a new way for the discovery and design of antivirals against NVs. A saliva-based enzyme immune assay (EIA) was used to screen a synthetic-compound library for inhibition of the binding of norovirus-like particles to HBGA receptors. Among 5,000 compounds tested in the first round of screening, 153 compounds exhibited >50% inhibition of the binding of VA387 (an NV that binds to A, B, and H epitopes) to the A antigen in saliva at ~50 µg/ml, and 14 of the 153 compounds revealed strong inhibition, with a 50% effective concentration of <15 µM. Ten and 11 of the 14 compounds also revealed inhibition of the binding of VA387 to the B and H antigens, respectively. Seven and 6 of the 14 compounds also blocked the binding of the prototype Norwalk virus (A and H binder) to the A and H antigens, respectively. One compound significantly inhibited the binding of MOH (A and B binder) to the A and B antigens, but no compound revealed any inhibitory effect on the binding of a Lewis binding strain (VA207) to the Lewis antigens. The EIA is a high-throughput method for large-scale library screening for antivirals against NVs. Studies to further characterize the lead compounds and to screen additional compounds for other NVs are ongoing in our laboratory.

* Corresponding author. Mailing address: Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave., Cincinnati, OH 45229-3039. Phone: (513) 636-0119. Fax: (513) 636-7655. E-mail: Jason.Jiang{at}cchmc.org.

{triangledown} Published ahead of print on 23 October 2006.

Antimicrobial Agents and Chemotherapy, January 2007, p. 324-331, Vol. 51, No. 1
0066-4804/07/$08.00+0     doi:10.1128/AAC.00627-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Cannon, J. L., Lindesmith, L. C., Donaldson, E. F., Saxe, L., Baric, R. S., Vinje, J. (2009). Herd Immunity to GII.4 Noroviruses Is Supported by Outbreak Patient Sera. J. Virol. 83: 5363-5374 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»